Literature DB >> 34286442

CXCL13 Signaling in the Tumor Microenvironment.

Muzammal Hussain1,2, Jinsong Liu3,4, Gui-Zhen Wang5, Guang-Biao Zhou6.   

Abstract

Chemokines have emerged as important players in tumorigenic process. An extensive body of literature generated over the last two or three decades strongly implicate abnormally activated or functionally disrupted chemokine signaling in liaising most-if not all-hallmark processes of cancer. It is well-known that chemokine signaling networks within the tumor microenvironment are highly versatile and context-dependent: exert both pro-tumoral and antitumoral activities. The C-X-C motif chemokine ligand 13 (CXCL13), and its cognate receptor CXCR5, represents an emerging example of chemokine signaling axes, which express the ability to modulate tumor growth and progression in either way. Collateral evidence indicate that CXCL13-CXCR5 axis may directly modulate tumor growth by inducing proliferation of cancer cells, as well as promoting invasive phenotypes and preventing their apoptosis. In addition, CXCL13-CXCR5 axis may also indirectly modulate tumor growth by regulating noncancerous cells, particularly the immune cells, within the tumor microenvironment. Here, we review the role of CXCL13, together with CXCR5, in the human tumor microenvironment. We first elaborate their patterns of expression, regulation, and biological functions in normal physiology. We then consider how their aberrant activity, as a result of differential overexpression or co-expression, may directly or indirectly modulate the growth of tumors through effects on both cancerous and noncancerous cells.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Antitumoral; B-cell differentiation; BCA-1; BLR1; CXCL13; CXCR5; Cancer progression; Chemokines; GPCR; Immune responses; Lymphoid neogenesis; Pro-umoral; Survival niche; TLSs; Tumor microenvironment

Year:  2021        PMID: 34286442     DOI: 10.1007/978-3-030-62658-7_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  97 in total

1.  Chemokines and leukocyte traffic.

Authors:  Federica Sallusto; Marco Baggiolini
Journal:  Nat Immunol       Date:  2008-09       Impact factor: 25.606

2.  A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1.

Authors:  M D Gunn; V N Ngo; K M Ansel; E H Ekland; J G Cyster; L T Williams
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 3.  CXCL13/CXCR5 signaling axis in cancer.

Authors:  Muzammal Hussain; Dickson Adah; Muqddas Tariq; Yongzhi Lu; Jiancun Zhang; Jinsong Liu
Journal:  Life Sci       Date:  2019-04-23       Impact factor: 5.037

4.  Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function.

Authors:  Jeffrey L Browning; Norm Allaire; Apinya Ngam-Ek; Evangelia Notidis; Jane Hunt; Steven Perrin; Roy A Fava
Journal:  Immunity       Date:  2005-11       Impact factor: 31.745

Review 5.  Chemokine Receptor Signaling and the Hallmarks of Cancer.

Authors:  R A Lacalle; R Blanco; L Carmona-Rodríguez; A Martín-Leal; E Mira; S Mañes
Journal:  Int Rev Cell Mol Biol       Date:  2016-11-30       Impact factor: 6.813

Review 6.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

Review 7.  The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer.

Authors:  Polina Weitzenfeld; Adit Ben-Baruch
Journal:  Cancer Lett       Date:  2013-10-18       Impact factor: 8.679

8.  CXC chemokines located in the 4q21 region are up-regulated in breast cancer.

Authors:  Ivan Bièche; Carine Chavey; Catherine Andrieu; Muriel Busson; Sophie Vacher; Ludovic Le Corre; Jean-Marc Guinebretière; Sandrine Burlinchon; Rosette Lidereau; Gwendal Lazennec
Journal:  Endocr Relat Cancer       Date:  2007-12       Impact factor: 5.678

9.  CXCL13 production by an established lymph node stromal cell line via lymphotoxin-beta receptor engagement involves the cooperation of multiple signaling pathways.

Authors:  Hidenori Suto; Tomoya Katakai; Manabu Sugai; Tatsuo Kinashi; Akira Shimizu
Journal:  Int Immunol       Date:  2009-02-27       Impact factor: 4.823

Review 10.  Biophysics of Tumor Microenvironment and Cancer Metastasis - A Mini Review.

Authors:  Bashar Emon; Jessica Bauer; Yasna Jain; Barbara Jung; Taher Saif
Journal:  Comput Struct Biotechnol J       Date:  2018-07-27       Impact factor: 7.271

View more
  6 in total

Review 1.  Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer.

Authors:  Jing Xu; Jing-Quan Li; Qi-Lei Chen; Elena A Shestakova; Vsevolod A Misyurin; Vadim S Pokrovsky; Elena M Tchevkina; Hu-Biao Chen; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

Review 2.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

3.  CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Yonglin Yi; Zhengang Qiu; Zifu Yao; Anqi Lin; Yimin Qin; Ruizhan Sha; Ting Wei; Yanru Wang; Quan Cheng; Jian Zhang; Peng Luo; Weitao Shen
Journal:  Front Cell Dev Biol       Date:  2022-01-11

4.  TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.

Authors:  Vivian Changying Jiang; Dapeng Hao; Preetesh Jain; Yijing Li; Qingsong Cai; Yixin Yao; Lei Nie; Yang Liu; Jingling Jin; Wei Wang; Heng-Huan Lee; Yuxuan Che; Enyu Dai; Guangchun Han; Ruiping Wang; Kunal Rai; Andrew Futreal; Christopher Flowers; Linghua Wang; Michael Wang
Journal:  Mol Cancer       Date:  2022-09-26       Impact factor: 41.444

Review 5.  Mechanism underlying circRNA dysregulation in the TME of digestive system cancer.

Authors:  Zeyu Wu; Xiao Yu; Shuijun Zhang; Yuting He; Wenzhi Guo
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

Review 6.  CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities.

Authors:  San-Hui Gao; Sheng-Zhi Liu; Gui-Zhen Wang; Guang-Biao Zhou
Journal:  Life (Basel)       Date:  2021-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.